Hospital Israelita Albert Einstein Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2012
NCT01861327
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Clinical Research Hospital Israelita Albert Einstein, Neurologist | Telemedicine Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil

Active Ingredients

Drugs in Phase 4 Trials (3)

cannabidiol (Epidiolex) (1 trial)

cannabigerol (1 trial)

tetrahydrocannabinol (1 trial)

Drugs in Other Trials (1)

carbon dioxide (dry ice) (1 trial)

Indications

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4